Astellas Announces Termination of Co-promotion with Viatris, Succession of Manufacturing and Marketing Approval, and Transfer of Distribution
for Lipitor® Tablets
TOKYO, April 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas" ) annouced that Astellas and Viatris Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, "Viatris") have agreed to end the co- promotion of a hypercholesterolemia and familial hypercholesterolemia treatment (HMG-CoA reductase inhibitor) "Lipitor® Tablets 5mg, 10mg" (generic name: atorvastatin calcium hydrate, "Lipitor") manufactured and sold by Astellas and co- promoted by both companies in Japan on July 31, 2021.
In accordance with this agreement, Viatris will solely promote and distribute Lipitor from August 1, 2021. Also, Viatris will take over the Marketing Authorization Holder of Lipitor from Astellas as of August 1, 2021.
The impact ot this transaction on Astellas' financial results of the current fiscal year ending March 31, 2021, is expected to be minor.
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contacts for inquiries or additional information:
Astellas Pharma Inc.
Corporate Advocacy & Relations
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
Astellas Pharma Inc. published this content on 01 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 April 2021 06:01:02 UTC.